The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy.
Rajiv DaveRachel O'ConnellTim RattayZoe TolkienNicola BarnesJoanna SkillmanPaula WilliamsonElizabeth ConroyMatthew GardinerAdrian HarnettCiara O'BrienJane BlazebyShelley PotterChris Holcombenull nullPublished in: BMJ open (2016)
Research ethics approval is not required for this study. This has been confirmed using the online Health Research Authority decision tool. This novel study will explore whether IBR impacts the time to delivery of adjuvant therapy. The study will provide valuable information to help patients and surgeons make more informed decisions about their surgical options. Dissemination of the study protocol will be via the Mammary Fold Academic and Research Collaborative (MFAC) and the Reconstructive Surgery Trials Network (RSTN), the Association of Breast Surgery (ABS) and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS). Participating units will have access to their own data and collective results will be presented at relevant surgical conferences and published in appropriate peer-reviewed journals.
Keyphrases
- breast reconstruction
- study protocol
- minimally invasive
- randomized controlled trial
- clinical trial
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- health information
- coronary artery disease
- peritoneal dialysis
- percutaneous coronary intervention
- cross sectional
- deep learning
- atrial fibrillation
- thoracic surgery
- placebo controlled